Parallax Volatility Advisers’s Ginkgo Bioworks DNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
Sell
-13
Closed -$930 2349
2023
Q2
$930 Sell
13
-37
-74% -$2.19K ﹤0.01% 2293
2023
Q1
$2.66K Sell
50
-10,933
-100% -$693K ﹤0.01% 2544
2022
Q4
$742K Sell
10,983
-3,650
-25% -$336K ﹤0.01% 1761
2022
Q3
$1.83M Buy
14,633
+7,133
+95% +$850K ﹤0.01% 1462
2022
Q2
$714K Buy
+7,500
New +$915K ﹤0.01% 1771

Other funds holding DNA

Parallax Volatility Advisers's DNA Position: Q3 2023 in Review

Parallax Volatility Advisers sold out of Ginkgo Bioworks (DNA) in Q3 2023, closing a stake of 2,496 shares — an estimated $186K sold.

Parallax Volatility Advisers first reported a position in DNA in Q4 2021 and held it in 4 quarters. The position peaked at $251K in Q4 2021. 349 funds tracked by Wall St. Rank hold DNA as of Q3 2023.

  • Parallax Volatility Advisers reported no remaining Ginkgo Bioworks position as of Q3 2023 after selling out during the quarter.
  • Parallax Volatility Advisers sold 2,496 Ginkgo Bioworks shares in Q3 2023, an estimated $186K.
  • Parallax Volatility Advisers first reported a position in Ginkgo Bioworks in Q4 2021 and held it in 4 quarters.
  • Parallax Volatility Advisers's Ginkgo Bioworks position peaked at $251K in Q4 2021.
  • 349 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2023.

Based on Parallax Volatility Advisers's 13F filing for Q3 2023, filed 14 Nov 2023.